New Legend Ph1 Trial for CD4 CAR-T (LB1901) in R/R T-Cell Lymphoma Posted
On Friday, January 15, a new Legend-sponsored Ph1 trial was observed on CT.gov for a first-in-human study of LB1901 (CD4 CAR-T) in ≥3L r/r T cell Lymphoma (TCL). Below, Celltelligence provides details for this trial and how LB1901 compares to Autolus’s AUTO4 program.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.